The Phase 1/2 trial will assess the safety and clinical activity of IMC-R117C, as a monotherapy and in combination with…
SAN FRANCISCO, Dec. 17, 2024 (GLOBE NEWSWIRE) -- American Shared Hospital Services (NYSE American: AMS) (the “Company” or “AMS”), a…
EYLEA HD demonstrated non-inferior vision gains with an every 8-week dosing regimen compared to EYLEA® (aflibercept) Injection 2 mg dosed…
WESTPORT, Conn., Dec. 17, 2024 (GLOBE NEWSWIRE) -- Portage Biotech, Inc. (“Portage” or the “Company”) (NASDAQ: PRTG), a clinical-stage immuno-oncology…
SUNNYVALE, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- BioCardia, Inc. [Nasdaq: BCDA], a global leader in cellular and cell-derived therapeutics for…
TN-201 Well Tolerated at 3E13 vg/kg Dose AAV9 Capsid Demonstrated Robust Delivery of TN-201 Transgene to Heart Muscle Cells Resulting…
NEW YORK, Dec. 17, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology…
As of December 16, 2024, the Company has repurchased a total of 102,405 shares at an average price of $1.9869…
Agreement Supports Phase IIb and Future Phase III Trial Development,Addressing Critical Needs in Palliative Care Using Optimi's Natural Psilocybin ExtractVancouver,…
London, United Kingdom--(Newsfile Corp. - December 17, 2024) - Edison issues report on Borussia Dortmund (FSE: BVB) Borussia Dortmund is…